PUBLISHER: The Business Research Company | PRODUCT CODE: 1750891
PUBLISHER: The Business Research Company | PRODUCT CODE: 1750891
Acute repetitive seizures refer to a condition in which a person experiences multiple seizures within a short period, typically occurring within a 24-hour timeframe. These seizures often happen in quick succession, without a return to normal consciousness or baseline neurological function between episodes. They may be triggered by factors such as brain injury, infections, metabolic disturbances, or underlying neurological disorders.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The main drug types used for managing acute repetitive seizures include benzodiazepines, antiepileptic drugs, barbiturates, and other related medications. Benzodiazepines are fast-acting drugs that help calm excessive brain activity, stopping acute seizures and preventing status epilepticus. These medications are administered via various routes, including intranasal, rectal, oral, and others. They are commonly used in hospitals, clinics, and home care settings by various end users.
The acute repetitive seizures market research report is one of a series of new reports from The Business Research Company that provides acute repetitive seizures market statistics, including the acute repetitive seizures industry global market size, regional shares, competitors with the acute repetitive seizures market share, detailed acute repetitive seizures market segments, market trends, and opportunities, and any further data you may need to thrive in the acute repetitive seizures industry. This acute repetitive seizures market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The acute repetitive seizures market size has grown rapidly in recent years. It will grow from $3.13 billion in 2024 to $3.51 billion in 2025 at a compound annual growth rate (CAGR) of 12.0%. The growth observed during the historic period can be attributed to the rising prevalence of epilepsy, increasing awareness of seizure management, growth in the use of rescue medications, improvements in diagnostic capabilities, and the expansion of healthcare access.
The acute repetitive seizures market size is expected to see rapid growth in the next few years. It will grow to $5.44 billion in 2029 at a compound annual growth rate (CAGR) of 11.6%. The growth projected for the forecast period can be attributed to the growing demand for non-invasive treatments, increasing investment in epilepsy research, the rising adoption of wearable seizure monitors, the expansion of telemedicine in neurology, and government initiatives aimed at improving epilepsy care. Key trends in the forecast period include the adoption of AI in seizure prediction, integration of digital health solutions, expanding clinical trials for innovative treatments, the development of gene therapies for epilepsy, and the creation of novel drug formulations.
The increasing prevalence of neurological disorders is expected to drive the growth of the acute repetitive seizures market. Neurological disorders affect the brain, nerves, or spinal cord, leading to issues with movement, speech, cognition, or other body functions. The rise in these conditions is largely due to an aging population, as older adults are more susceptible to degenerative brain changes, heightening the risk of diseases such as Alzheimer's, Parkinson's, and stroke. Acute repetitive seizures are a significant concern in the progression of neurological disorders, as they contribute to neuronal damage, cognitive decline, and long-term complications, making early intervention crucial. For example, according to the Alzheimer's Association, by 2023, approximately 6.7 million Americans aged 65 and older were living with Alzheimer's dementia, with projections estimating that number will increase to 13.8 million by 2060. Therefore, the rising prevalence of neurological disorders is a key factor driving the growth of the acute repetitive seizures market.
Key players in the acute repetitive seizures market are developing innovative drug delivery technologies, such as the benzodiazepine buccal film, to improve drug absorption, provide rapid seizure relief, and enhance patient convenience. This buccal film, a thin dissolvable sheet containing benzodiazepine medication, is placed inside the cheek, where it quickly absorbs through the oral mucosa to deliver rapid relief. It is designed to manage acute repetitive seizures by swiftly releasing the medication into the bloodstream, reducing seizure duration and frequency. In December 2024, Aquestive Therapeutics Inc. received seven years of orphan drug exclusivity (ODE) from the U.S. Food and Drug Administration (FDA) for its product Libervant (diazepam) buccal film. Libervant is used for the acute treatment of intermittent seizure clusters and acute repetitive seizures. It acts as a central nervous system depressant, enhancing the effects of gamma-aminobutyric acid (GABA) to reduce seizure activity.
In January 2022, Aculys Pharma, Inc., a Japanese biopharmaceutical company specializing in neurological treatments, entered into a partnership with Neurelis, Inc. This collaboration aims to expand access to innovative therapies for neurological conditions, particularly seizure management. The companies secured licensing rights for advanced therapies, such as VALTOCO, a nasal spray used to manage seizure clusters and acute repetitive seizures. Neurelis, Inc., based in the U.S., focuses on neurology and psychiatry treatments, further enhancing their ability to deliver targeted therapies for patients suffering from these debilitating conditions.
Major players in the acute repetitive seizures market are Pfizer Inc., Sanofi S.A., Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Boehringer Ingelheim International GmbH, Bausch Health US LLC., UCB S.A., Eisai Co. Ltd., Sun Pharmaceutical Industries Ltd., Hikma Pharmaceuticals PLC, Zydus Lifesciences Limited, Endo International plc, Lupin Limited, Amneal Pharmaceuticals LLC, Aquestive Therapeutics Inc., Neurelis Inc., Grupo Ferrer Internacional S.A., UpsherSmith Laboratories LLC, Aculys Pharma Inc.
North America was the largest region in the acute repetitive seizures market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in acute repetitive seizures report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the Acute Repetitive Seizures market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The acute repetitive seizures market consists of revenues earned by entities by providing services such as emergency medical services, hospital-based treatment, telemedicine and remote monitoring, specialty pharmacy services, seizure action plan development. The market value includes the value of related goods sold by the service provider or included within the service offering. The acute repetitive seizures market also includes sales of intranasal rescue medications, rectal diazepam gel, anticonvulsants, and wearable seizure detection devices. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Acute Repetitive Seizures Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on acute repetitive seizures market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for acute repetitive seizures ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The acute repetitive seizures market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.